Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

NCT04932564 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class

Stopped Issues with recruitment. Practice changes, including leflunomide use for CMV, have led to a lack of musculoskeletal GVHD cases. Only one patient enrolled in the trial will continue treatment as per standard care.

Conditions

Interventions

Sponsor

Tata Memorial Centre